Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent subtype c gp120 + aluminum hydroxide
- Development stage
- Unknown
- Lead developer
- National Institutes of Health
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine candidate composed of two recombinant HIV-1 envelope glycoprotein 120 (gp120) proteins from subtype C strains (TV1.C and 1086.C), each at a dose of 100 μg, formulated with aluminum hydroxide as an adjuvant. This vaccine is designed to induce immune responses against HIV-1 subtype C and is typically used as a protein boost following priming with a canarypox vector-based HIV vaccine. The mechanism of action involves eliciting anti-gp120 antibody responses and CD4 T cell responses targeting the HIV-1 envelope protein. The primary indication is for the prevention of HIV infection, particularly in regions where subtype C predominates. Development has been led by public sector organizations such as the Vaccine Research Center (NIAID, NIH), with clinical trials conducted in collaboration with other partners[1][4][6].
- Other names
- bivalent clade C gp120/alumbivalent subtype C gp120/alumbivalent clade C gp120 + alum
02
Targets
gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)
Beyond the preview
Go deeper on bivalent subtype c gp120 + aluminum hydroxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent subtype c gp120 + aluminum hydroxide.